venture 2015
Companies for tomorrow

award ceremony: the best business plans and business ideas for tomorrow
Preface

Dear >>venture<< community,

We are very proud to celebrate our jubilee edition of >>venture<< and to announce the winners of >>venture<< 2015. For the jubilee edition, we revised our initiative’s format. As of this year, >>venture<< will take place yearly instead of biannually. This new format, which combines the business plan and business idea phases into one competition with two tracks, has now been sent on its maiden voyage these last few months. We created a whole new series of events enabling our participants to find co-founders and employees and get in touch with coaches, investors and industry experts. Thus, we integrated >>venture<< even better into the dense and dynamic Swiss start-up ecosystem in order to enable more people to turn their ideas into businesses.

For our anniversary edition we also developed a state-of-the-art online platform to fit the needs of the participating teams. Looking back on twenty years and ten editions of >>venture<<, our initiative grew considerably, bearing in mind it was once a start-up itself. A deeper insight into the history of >>venture<<, its founders, its alumni and the ever changing Swiss start-up-scene is provided in our freshly released book with the title «>>venture<< graduates go to the top». For making all of these ten editions possible, we want to especially thank our jury members, coaches and our advisory board for their continued support!

We congratulate the >>venture<< 2015 winners and wish them – and >>venture<< ! – the best of success in the future!
<table>
<thead>
<tr>
<th>Content</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Summary</td>
<td>6</td>
</tr>
<tr>
<td><strong>venture</strong> in numbers</td>
<td>8</td>
</tr>
<tr>
<td>The finalists</td>
<td>14</td>
</tr>
<tr>
<td>Top 5 business plans</td>
<td>16</td>
</tr>
<tr>
<td>Top 6-25 business plans</td>
<td>26</td>
</tr>
<tr>
<td>Top 5 business ideas</td>
<td>28</td>
</tr>
<tr>
<td>Top 6-25 business ideas</td>
<td>38</td>
</tr>
<tr>
<td>Advisory board members</td>
<td>40</td>
</tr>
<tr>
<td>Coaches &amp; jurors</td>
<td>41</td>
</tr>
<tr>
<td>Contact</td>
<td>45</td>
</tr>
</tbody>
</table>
Switching from the biannual to the annual format and parallelizing the business idea and business plan phase have been hugely successful. Events almost by the week, most of them taking place in Zurich as well as in Lausanne, led to a total of 428 registered participants. The participants belong to 107 teams that submitted a business idea, and 95 that submitted a business plan. This was well above our expectations for the first year in the yearly format.

Compared to last year’s edition of >>venture>>, more of the participating teams, that is one third, submitted a project related to information technology. About one fourth of the projects are in consumer goods and one fifth in healthcare. As to the affiliation of the participants, 25% are affiliated with the ETHZ, 15% with the EPFL, and some 30% with other Swiss universities and universities of applied sciences. We have 22% women amongst the team members.

Half of the participating teams took the opportunity to get mentored by our distinguished group of 155 coaches. We are convinced that this support is a huge help for our participants and that some of these coaching relationships will last beyond >>venture>> 2015.

On top of our coaching offer, all teams received written feedback on their business ideas and plans by our 93 jurors. As in all >>venture>> editions, coaches and jurors worked in an honorary capacity on top of their normal workload.

Taking a quick glance at our top five teams in both the business idea and business plan category shows us that the federal institutes of technology still are in the lead when it comes to marketable innovation: eight of ten teams are affiliated to either the EPFL or the ETHZ.

>> We wrote a business plan while we were working on our doctoral theses. We probably wouldn’t have written it so quickly if it hadn’t been for the deadline set by the very first >>venture>> competition. The competition acted like a catalyst for us, and it helped us to think big. >>

Felix Mayer, Moritz Lechner Sensirion
<table>
<thead>
<tr>
<th>in numbers</th>
<th>in numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Key figures of venture 2015</td>
<td>Projects submissions by Industry</td>
</tr>
</tbody>
</table>

**venture 2015 supported ...**

- 428 participants
- 238 teams registered¹ to venture
- 95 business plans submitted
- 107 business ideas submitted

**... and delivered ...**

- 17 events to venture participants
- 25 potential new team mates to participating startups
- 40 hours of expert advice at events
- 244 1-on-1 coaching sessions
- 604 feedbacks to participating teams for their submitted projects

---

¹ 36 teams registered to venture but did not submit their business plan or idea for evaluation
**Most recent university affiliation**
Number of individuals, 428 = 100%

<table>
<thead>
<tr>
<th>University Type</th>
<th>Number</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>ETH Zurich</td>
<td>109</td>
<td>25%</td>
</tr>
<tr>
<td>Swiss university</td>
<td>93</td>
<td>23%</td>
</tr>
<tr>
<td>Foreign university</td>
<td>86</td>
<td>20%</td>
</tr>
<tr>
<td>EPFL</td>
<td>62</td>
<td>14%</td>
</tr>
<tr>
<td>Swiss universities of applied sciences</td>
<td>55</td>
<td>13%</td>
</tr>
<tr>
<td>No university affiliation</td>
<td>23</td>
<td>5%</td>
</tr>
</tbody>
</table>

**Gender**

<table>
<thead>
<tr>
<th>Gender</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>78</td>
</tr>
<tr>
<td>Female</td>
<td>22</td>
</tr>
</tbody>
</table>

**Age distribution of participants**
Number of individuals, 428 = 100%

<table>
<thead>
<tr>
<th>Age Range</th>
<th>Number</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;25</td>
<td>55</td>
<td>13%</td>
</tr>
<tr>
<td>25-29</td>
<td>113</td>
<td>26%</td>
</tr>
<tr>
<td>30-34</td>
<td>107</td>
<td>25%</td>
</tr>
<tr>
<td>35-39</td>
<td>72</td>
<td>17%</td>
</tr>
<tr>
<td>40-44</td>
<td>40</td>
<td>9%</td>
</tr>
<tr>
<td>45-49</td>
<td>22</td>
<td>5%</td>
</tr>
<tr>
<td>&gt;50</td>
<td>19</td>
<td>5%</td>
</tr>
</tbody>
</table>

**Professional status**
Number of individuals, 428 = 100%

- Currently unemployed: 19 (4%)
- Student or PhD student: 127 (29%)
- Employed: 159 (37%)
- Self-employed: 129 (30%)
the Switzerland wide competition

Number of submitted projects

- Genferseeregion: 56
- Espace Mittelland: 7
- Nordwestschweiz: 17
- Zurich: 91
- Zentralschweiz: 11
- Ostschweiz: 7
- Tessin: 5
- Fürstentum Liechtenstein: 1
- Other*: 7

*Projects submitted from abroad planning to incorporate company in Switzerland
The 25 Business plan finalists

Adaptricity 26
Advanon 26
AquAero 26
Comfy 26

Event Space Market 26
Gamaya 18
GoalHub 26
Interprefy 27
Unono 27
Visible Impact 27
Xorlab 27

The 25 Business idea finalists

Arabic Friendly 38
Eye Spoke Glasses 38
pocket ski instructor 38
Waterbird - 3D Water Printing 39
Tropical Mountains 39

ROVESCO 39
TapTools 36
The Construct 39
Sensetag 32

Consumer Goods and services

CuTISS 16
Dermolockin 26
Inositec 27
Intento 27
PB&B 27
Xsensio 27
ZuriMED 24

Industrial

Equippo 26
microGauge 22

Information Technology

Gaia 26
Goodwall 26
Post Auction 27
RedTape 27
Verity Studios 27
Xsensio 27

Healthcare

CUTISS 16
Dermolockin 26
Inositec 27
Intento 27
PB&B 27
Xsensio 27
ZuriMED 24

Consumer Goods and services

Pregnostics 30
Biocatalytic medicinal chemistry 38
iPhaTech 38
myDNA 38
Nematrix 38
Spinal Dynamics 39
SUN bioscience 34

FireHUD 28
GiveMe5 38
Kickshops 38
McFahrscule 38
MediPebble 38
RobSense-CNAV 39
synaesthesia.com 39
Tasti 39
TimeGenie 39

Others

Others
Deep and large skin defects (e.g., after burns or tumor resections) represent a huge burden on the patients: the wounds heal slowly and a long hospitalization time is needed. Starting from a very small patient biopsy, CuTISS developed an innovative technology to engineer large skin transplants with the aim to provide a better and faster healing of the wounds, less scars and improved functionality of the skin. In other words, CuTISS aims at solving a huge unmet medical need for millions of patients worldwide!

Why CuTISS

Deep and large skin defects (e.g., after burns or tumor resections) represent a huge burden on the patients: the wounds heal slowly and a long hospitalization time is needed. Starting from a very small patient biopsy, CuTISS developed an innovative technology to engineer large skin transplants with the aim to provide a better and faster healing of the wounds, less scars and improved functionality of the skin. In other words, CuTISS aims at solving a huge unmet medical need for millions of patients worldwide!

CuTISS
Dr. Daniela Marino

<table>
<thead>
<tr>
<th>Industry</th>
<th>Pharmaceuticals, biotechnology &amp; life sciences / Biotechnology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Place</td>
<td>Zürich</td>
</tr>
<tr>
<td>Affiliation</td>
<td>Uni Zürich</td>
</tr>
<tr>
<td>Contact</td>
<td><a href="mailto:daniela.marino@kispi.uzh.ch">daniela.marino@kispi.uzh.ch</a></td>
</tr>
</tbody>
</table>

What we do

Deep skin wounds heal badly, developing into debilitating, permanent, disfiguring scars that require intense medical and home care. CuTISS now offers individually customized, minimally scarring skin grafts bio-engineered from a small piece of the patient’s skin.

What we need

CuTISS is a young start-up that faces the challenge of bringing innovation into the regenerative personalized medicine field. Substantial financial support, excellent regulatory expertise and solid industrial partnerships will be required to reach our goals.

Why CuTISS

Deep and large skin defects (e.g., after burns or tumor resections) represent a huge burden on the patients: the wounds heal slowly and a long hospitalization time is needed. Starting from a very small patient biopsy, CuTISS developed an innovative technology to engineer large skin transplants with the aim to provide a better and faster healing of the wounds, less scars and improved functionality of the skin. In other words, CuTISS aims at solving a huge unmet medical need for millions of patients worldwide!
Gamaya offers an elegant solution to the growing need to maximise global food production through more efficient agricultural practices. Their novel crop imaging technology is a significant advance over the competition and their data analysis software offers a clear advantage in delivering more robust data enabling the target customers, farmers/agronomists, to act decisively on the information. The management team are experienced and the business plan provides a clear path to the market.

Andrew Parker, member of the jury committee

Gamaya provides an integrated solution for large-scale monitoring and diagnostics of crops for precision agriculture. Gamaya acquires imaging data using sensors mounted on drones, and translates the data into actionable information for farmers, such as optimum rates of application for fertilisers and crop protection chemicals, as well as early alerts for disease, pests and weeds.

What we need
Currently we are looking to raise EUR 1.5-2 mio by the end of the summer; this will allow us to complete the development and validation of our products and data processing software by the end of this year, and to start our commercial services at the rate of $10 per ha. We have a list of potential investors in various phases of due diligence process.

Industry | Software & services / Agritech
Place | Lausanne
Affiliation | EPFL
Contact | info@gamaya.com

Why Gamaya
Gamaya offers an elegant solution to the growing need to maximise global food production through more efficient agricultural practices. Their novel crop imaging technology is a significant advance over the competition and their data analysis software offers a clear advantage in delivering more robust data enabling the target customers, farmers/agronomists, to act decisively on the information. The management team are experienced and the business plan provides a clear path to the market.
The approach of Inositec is very innovative since it uses a mechanism which prevents damage to the patient and avoids resistances like with antibiotics. The use of an easily accessible small molecule will make it possible to achieve the proof of concept stage fast. Tests with animals have already shown positive results. The team combines strong scientific and business experience and has great potential to translate this technology into the clinic.

**Inositec**
Mattias Ivarsson, Bastien Castagner
Jean-Christophe Leroux

<table>
<thead>
<tr>
<th>Industry</th>
<th>Pharmaceuticals, biotechnology &amp; life sciences / Pharmaceuticals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Place</td>
<td>Zürich</td>
</tr>
<tr>
<td>Affiliation</td>
<td>ETH</td>
</tr>
<tr>
<td>Contact</td>
<td><a href="mailto:info@inositec.com">info@inositec.com</a></td>
</tr>
</tbody>
</table>

**What we do**
Inositec is a drug development project at the preclinical proof-of-concept stage with a small molecule for the treatment of *Clostridium difficile* infection, a bacterial infection of the colon that has become the most common healthcare-associated infection.

**What we need**
Inositec is looking for an expert in drug development to join the team after completion of the pre-clinical proof-of-concept, and will require a multi-million financing round to support its development activities.

**Why Inositec**
The approach of Inositec is very innovative since it uses a mechanism which prevents damage to the patient and avoids resistances like with antibiotics. The use of an easily accessible small molecule will make it possible to achieve the proof of concept stage fast. Tests with animals have already shown positive results. The team combines strong scientific and business experience and has great potential to translate this technology into the clinic.

Silke Meyns, member of the jury committee
The microGauge project aims to develop and commercialize next-generation pressure sensors for industrial vacuum coating systems. The proposed high-precision, full-range sensor offers means to replace up to four state-of-the-art sensors with one single compact gauge.

In order to move from our functional prototype to a first commercial product with short time-to-market, we are looking for investors to secure a first financial round. We would also like to strengthen the team with new highly motivated and skilled members.

Why microGauge

The semiconductor industry, thin film coating and many other industrial processes need pressure sensors for vacuum. With the existing technologies up to four individual gauges are needed to cover the entire process pressure range. microGauge has developed a novel measurement principle which allows to cover the whole range of pressure and also eliminates other shortcomings of the existing sensors. microGauge provides a real value added for their customers. The market is very specialized and therefore limited but growing. The decision to focus on one market segment initially is correct and the implementation plan is convincing. The team is technologically very strong and has also some industrial experience.

Josef A. Dürr, member of the jury committee
Knee ligament injuries are among the most common and severe musculoskeletal traumas. ZuriMED is an innovative team specialized in orthopedic biomechanics and biomaterials that has developed a disruptive technology with potential to revolutionize anterior cruciate ligament reconstruction.

The team possesses strong technical and clinical backgrounds but requires expert partners in legal and regulatory affairs. We have initiated the design transfer from prototype to ISO certified product, and seek Swiss production partners. In parallel we will enlarge our clinical network and establish a medical advisory board of opinion leaders.

**What we do**

Zurimed improves the surgical treatment of knee ligament reconstruction after injury of the anterior cruciate ligament (ACL). Their BTB-Conversion-Kit allows to combine a less painful graft harvesting technique with a high performance ACL reconstruction. The patent protected technology can be used in a nearly cost-neutral combination with the vast majority of existing ACL reconstruction techniques. The patient benefits of the product are evident and there should be a good acceptance of this innovative solution in the surgical community. The team has delivered a well thought thru business plan and is aware of the weaknesses and risks that will have to be addressed during the development of the company.

**Why ZuriMED**

Valentin Chapero, member of the jury comittee
Finalists (in alphabetical order)

Adaptricity (ETH) Adaptricity, a spin-off company of ETH Zurich, develops innovative decision support software tools for simulation, optimization, and planning of power systems.

Advanon (Auständische Universität / Wohnort Zürich) Advanon offers an online platform that allows SMEs to sell their open invoices directly to financial investors.

AquAero (FHNW) AquAero develops energy efficient mobile air wells which extract large amounts of drinking water from the air even in a desert to an affordable price.

Comfy (UniSG) Comfy is a LED light bulb, which acts as an alarm in a bulb. It prevents intruders by simulating presence, notifying the user and scaring the intruder away with a flashing light.

Dermolockin (Uni SG) Dermolockin is an infrared imaging device for dermatological applications, measuring and imaging small variations of the skin’s thermo-physical properties in a non-invasive and non-contact manner.

Equippo (UniSG) Global Deals, Made Easy: The Equippo Marketplace offers quality used construction equipment to buyers around the globe.

Event Space Market (ETH) Event Space Market (ESM) is the first internet platform providing full transparency on availability of event space in hotels around the world.

Gaia (Uni Liechtenstein) Gaia is developing an urban gardening set, consisting of a growing box, soil, integrated fertilizer, seeds, and instructions.

GoalHub (ETH) GoalHub provides the platform and syntax for executives to drive agile management in their organisations: define and orchestrate work Twitter-style.

Goodwall (Unil) Goodwall is a social network for highschool students to find their university match, show their achievements while connecting with universities and other students.

Intento (EPFL) Intento develops wearable, effective, and easy-to-use solutions for the rehabilitation of paralyzed stroke patients, tracking therapy and usage data.

Interprefy (ETH) Interprefy offers an Internet-based platform for simultaneous interpreting at conferences and similar events. Delegates use their smartphones as headsets and interpreters work from home.

PB&B (Uni Geneva) PB&B is a medtech startup developing a new generation of natural fillers and anti-aging medicine for plastic surgeons and dermatologists.

Post Auction (Auständische Uni / Wohnort Zürich) PostAuction centralizes all unsold and stored items from premium auction houses around the world on one platform and markets these to collectors internationally.

RedTape (EPFL) Family Office democratized and accessible to all. RedTape reduces paperwork from four hours per month down to 20min and offers a dedicated personal assistant.

Unono (Unil) Unono is a web platform which aims to empower everyone’s university experience, improving the way to consume information and communicate within the academic realm.

Visible Impact (Uni BS) Visible Impact lets organisations manage their projects, measure and visualize data and communicate their social impact online.

Verity Studios (ETH) Verity Studios AG develops a new breed of interactive and autonomous flying machines.

Xorlab (ETH) xorlab’s core technology, SploitGuard, detects and prevents software-based attacks that exploit previously unknown software vulnerabilities (zero-days attacks).

Xsensio (EPFL) Xsensio develops wearable, bio-compatible and non-intrusive devices that track biochemical information in human bodies and provide early warnings before critical thresholds are met.
Making the work of firemen less dangerous and more efficient contributes to the “greater good”, but with a clear value proposition and well-defined market segments, this project also has the potential to become commercially successful. With a combination of a driven team, new augmented reality technologies and ever more affordable system components, the timing for bringing this type of solution to market seems excellent.

FireHUD helps firemen to see through smoke and darkness by showing a thermal image overlay on an augmented reality mask. This increases their situational awareness and capacity to search for victims, therefore making their work safer and more efficient.

What we need

We are looking for investing partners to finish the prototyping phase and start industrialization, and new co-founders/employees with experience in robust hardware design to address the challenges of sensitive optics and electronics in a rough environment.

Why FireHUD

Making the work of firemen less dangerous and more efficient contributes to the “greater good”, but with a clear value proposition and well-defined market segments, this project also has the potential to become commercially successful. With a combination of a driven team, new augmented reality technologies and ever more affordable system components, the timing for bringing this type of solution to market seems excellent.

Martijn Bosch, Adrien Birbaumer

<table>
<thead>
<tr>
<th>Industry</th>
<th>Software &amp; services / Application software</th>
</tr>
</thead>
<tbody>
<tr>
<td>Place</td>
<td>Lausanne</td>
</tr>
<tr>
<td>Affiliation</td>
<td>EPFL</td>
</tr>
<tr>
<td>Contact</td>
<td><a href="mailto:info@firehud.com">info@firehud.com</a></td>
</tr>
</tbody>
</table>

Ulf Claesson, member of the jury committee
Pregnostics has developed a novel method to identify women at risk of preterm birth with a much higher accuracy compared to the gold standard. The method is easy to use and safe to apply and has already been tested in a first clinical trial. Based on the very promising results, a concise business idea and a clear market need the jury expects this business to be greatly realistic.

**What we do**

Pregnostics is developing a diagnostic tool that measures the cervical stiffness in pregnant women. Monitoring cervical stiffness allows to identify women at risk of preterm birth, thus solving the problem of preterm birth risk assessment in pregnancy.

**What we need**

A business oriented team member interested in the development of our business strategy, seed capital from an investor with experience in the MedTech market, engineering and manufacturing partners for product realization.

**Why Pregnostics**

Pregnostics has developed a novel method to identify women at risk of preterm birth with a much higher accuracy compared to the gold standard. The method is easy to use and safe to apply and has already been tested in a first clinical trial. Based on the very promising results, a concise business idea and a clear market need the jury expects this business to be greatly realistic.

---

**Pregnostics**

Sabrina Badir, Michela Perrini, Francisco Feijó Delgado

<table>
<thead>
<tr>
<th>Industry</th>
<th>Health care equipment &amp; services / Health care equipment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Place</td>
<td>Zürich</td>
</tr>
<tr>
<td>Affiliation</td>
<td>ETH</td>
</tr>
<tr>
<td>Contact</td>
<td><a href="mailto:badirs@ethz.ch">badirs@ethz.ch</a></td>
</tr>
</tbody>
</table>

---

Marjan Kraak, member of the jury committee
In modern society, the need to measure is just increasing in order to be able to control, but also continuously improve in nearly all areas of human activity, at times in challenging places. I nominated Sensetag, since it addresses these needs with a novel technology. Furthermore, I was impressed how concrete they have already made their business idea (!). Needless to say, they need to complement their team on the business side and move fast forward in a focused manner to seize this market opportunity.

Søren Bjønness, member of the jury committee

---

**Sensetag**
Michela Puddu, Gediminas Mikutis

<table>
<thead>
<tr>
<th>Industry</th>
<th>Oil, gas &amp; other fuels / Oil &amp; gas drilling</th>
</tr>
</thead>
<tbody>
<tr>
<td>Place</td>
<td>Zürich</td>
</tr>
<tr>
<td>Affiliation</td>
<td>ETH</td>
</tr>
<tr>
<td>Contact</td>
<td><a href="mailto:sensetag@ethz.ch">sensetag@ethz.ch</a></td>
</tr>
</tbody>
</table>

---

**What we do**

We have developed a class of patent-pending, smart, inexpensive, ultrasmall DNA-based tracers able to measure a range of properties (temperature, oxidative stress, light, pH) in challenging commercial, industrial, research or clinical settings (e.g. deep underground, within live cells).

---

**Why Sensetag**

In modern society, the need to measure is just increasing in order to be able to control, but also continuously improve in nearly all areas of human activity, at times in challenging places. I nominated Sensetag, since it addresses these needs with a novel technology. Furthermore, I was impressed how concrete they have already made their business idea (!). Needless to say, they need to complement their team on the business side and move fast forward in a focused manner to seize this market opportunity.

---

**What we need**

A strategic partner and larger field projects for the transition from prototype to on-site applications.

---

Søren Bjønness, member of the jury committee
SuN bioscience is targeting an attractive segment in the pharma industry as it brings an innovative solution to personalized medicine implementation reducing unreliable manual manipulation. The proposed solution provides value to its customers. In a clever step by step approach, SuN bioscience will address first the needs of the research market, then the pharmaceutical laboratories and ultimately the clinics. This will allow sequential investment with clear intermediary proof of concept.

Véronique Stephan, member of the jury committee

---

**What we do**

SuN bioscience is a biotech company that provides next generation cell culture platforms. We specialize on making three-dimensional organotypic cultures faster, more efficient and more reproducible in order to develop better and new drugs and to define their efficacy in a patient-specific manner.

**What we need**

Our near future main priority lies in the scaling of manufacturing, for which we seek collaborations with robotic specialists. Moreover, we focus on building strong customer relations especially also in the biotech and pharmaceutical industry, where we look for early adopters.

---

### SUN bioscience

Sylke Hoehnel, Nathalie Brandenberg

<table>
<thead>
<tr>
<th>Industry</th>
<th>Pharmaceuticals, biotechnology &amp; life sciences / Life sciences tools &amp; services</th>
</tr>
</thead>
<tbody>
<tr>
<td>Place</td>
<td>Lausanne</td>
</tr>
<tr>
<td>Affiliation</td>
<td>EPFL</td>
</tr>
<tr>
<td>Contact</td>
<td><a href="mailto:info@sunbioscience.ch">info@sunbioscience.ch</a></td>
</tr>
</tbody>
</table>

---

**Why SUN bioscience**

SUN Bioscience is targeting an attractive segment in the pharma industry as it brings an innovative solution to personalized medicine implementation reducing unreliable manual manipulation. The proposed solution provides value to its customers. In a clever step by step approach, SUN bioscience will address first the needs of the research market, then the pharmaceutical laboratories and ultimately the clinics. This will allow sequential investment with clear intermediary proof of concept.

Véronique Stephan, member of the jury committee
TapTools fulfills a strong need for nondestructive testing of materials being used in growing markets such as the composite industry. Their technology is highly innovative and can be used as handheld device as well as for real-time testing in production lines. The envisaged strategy to offer first a handheld device followed by engineered production equipment is optimal for entering this market. The team is technologically very strong and has a clear and a realistic implementation plan.

Walter Looser, member of the jury committee
Finalists (in alphabetical order)

Arabic Friendly (Uni Lugano) Arabic Friendly ensures that Arab tourists feel comfortable during their holiday in Europe by supplying them with appropriate conditions in hotels and restaurants.

Bioanalytic medicinal chemistry (ETH) We are using bacteria to improve the drug optimization process. This platform is being applied to develop new neuroactive steroid drug candidates.

EyeSpoke Glasses (ETH) We merge 3D printing and mobile 3D scanners to create sunglasses that are sculpted to fit the customer’s face and tailored to express the customer’s personality.

GiveMe5 (Uni GE) GiveMe5 is a mobile service dedicated to the creation of events between friends in only a few clicks.

«iPhaTech» (Foreign university) We provide new products and processes to enable development and manufacture of high-quality pharmaceuticals at reduced cost and time.

Kickshops (Kaleidos FH) Kickshops makes it super easy to open an online shop, upload your products, and accept payments. Works with whatever device is in your pocket.

McFahrschule (Uni ZH) McFahrschule virtualizes a substantial part of the driver’s education – practicing basic skills and driving in traffic – by transferring it to driving simulators.

MediPebble (Uni SG) A photo sharing community for medical professionals to safely share and discuss clinical cases and medical treatments with fellow colleagues around the world.

myDNA (EPFL) myDNA delivers to personalized genomic diagnostics in a clinically relevant form, so that doctors can translate it into actionable and precise treatment.

Nematrix (EPFL) Nematrix builds the first automated microfluidic-based platform for high-content screening on worms.

pocket ski instructor (ETH) pocket ski instructor is an app allowing skiers to improve independently. By skiing on a designed slope, users will receive feedbacks and videos of useful exercises directly to their smartphone.

RobSense–CNAV (ETH) We create, low-cost and compact GNSS navigation solution with centimetres accuracy for Robotics, UAVs and any high precision required applications.

ROVENSO (EPFL) We design, manufacture and market agile robots that preserve human life from hazardous operations in nuclear decommissioning and emergency response.


synaesthesia.com (ETH) Synaesthesia-App is developing an App based on synaesthesia-principles (interconnection of the 5 senses – e.g. «smelling colors» or «assigning colors to letters of the alphabet»)

Tasti (EPFL) Tasti is an online platform connecting people who are looking for meals with people who want to cook. Users can find and request meals, or post meals they cook.

The Construct (Foreign university / Aargau) The Construct aims at providing a «WebEx-like» system allowing to upload 3D models of engineered parts (CAD) with other remote users using virtual reality or augmented reality technology.

Time Genie (ETH) TimeGenie offers a simple solution to the complex problem of planning and scheduling meetings. Its algorithms find the perfect time for all participants.

Tropical Mountains (ZHAW) 100% traceable biodegradable coffee capsules for Nespresso® machines with coffee of our farm in Peru, offering a waste solution for a market of 8.5 billion aluminium capsules.

Waterbird–3D Water Printing (ETH) Our vision is a 3D printer which produces large-scale, liquid 3D objects in motion. The device can interact with its surroundings and provides stunning effects.
Advisory board members

Juhani Anttila
Pascal Kiener
Calvin Grieder
Harriof Kottmann
Barend Fruithof
Christoph Loos
Christian Zahnd
Mauro Saladini
Frank Lehmman
Reinhard Ambros
Severin Schwan
Lukas Braunschweiler

Coaches & jurors (A–E)

Many thanks to all our coaches and jurors for their time and expertise!

Amstutz Patrick
Attas Bernard
Aykac Kaan
Baumann Brigitte
Baumgartner Peter
Bäumlin Peter
Becker René
Berenek Zanon Nicole
Berger Mark
Binz Kaspar
Bjønness Søren
Blarer Stefan
Boichat Romain
Braun Aron
Brunner Hans
Brunner Simon
Bührer Adrian
Buller Fabian
Burckhardt Peter
Burckhardt Peter E.
Caleffi Dario
Caritey Julien
Caro Adriel
Celia Indro
Chapero Valentin
Christen Gert
Christen Jakob Mariana
Claesson Ulf
Cometta Silvano
Crochat Olivier
Dängeli Sandra
Day Stefan
de Melo Isabelle
de Watteville Emmanuel
Decker Markus
Dennis John
Dequesne Romain
Derungs Bruno
Dobenecker Gabriele
Dubrulle François
Dudek Peter
Dürr Josef A.
Ebnöther Yves
Eleveld Rolf
### Coaches & jurors (E-K)

- Ernst Bettina
- Fantini Nicola
- Felber Josef
- Fischer Peter E.
- Florin Claude
- Fontana Kadri Vunder
- Frankenberger Sebastian
- Freuler Nikolaus K.
- Fülscher Jan
- Gaemperle Philippe
- Gambardella Antonio
- Gandar Marc
- Garcia Marcos
- Gigon Claire Marie
- Glauser Markus
- Gmür Walter
- Govinder Nanci
- Grabulovski Dragan
- Grzegorzekswk Marek
- Guirey Ronan
- Güttinger Jörg
- Gygax Ruedi
- Hacklin Aino
- Hamilton Rhea
- Hardtmuth Alexander
- Hartschen Michael
- Hatz Jann J.
- Hefti Jacques
- Hegarty Aoife
- Hess Stephan
- Hlib Michael
- Hofer Markus
- Hohl Heinz
- Hölling Matthias
- Hotz Peter
- Iwankowska Malgosia
- Jackson Krissy
- Jakl Martina
- Jenni Mario
- Kalt Adrian
- Kaltofen-Ehmann Arnd
- Keller Tiziana Villa
- Kirchhoff Katharina
- Kirschwer Lutz
- Knecht Stephan Otto
- Knecht Jürg
- Knecht Stephan
- Knight Christopher

### Coaches & jurors (K-R)

- Kobel Olivier
- Kraak Marjan
- Kreysel Matthias
- Krug Tom
- Krüsi Monika
- Kuhlen Francis
- Lang Markus
- Lewis Jim
- Looser Walter
- Loosli Mauro
- Mabillard Sébastien
- Margadant Reto
- Mariéthoz Jérôme
- Mariggi Giovanni
- Matthews Donat
- Mayer Felix
- McShane Alec
- Meyer Jörg
- Meyns Silke
- Milat Igor
- Moning Elisabeth
- Moser Markus
- Müller Ulf Christian
- Müller Adrian
- Munton Richard
- Naessens Wouter
- Nagel Christian
- Neau Jean-Charles
- Niederberger Martin
- Niedermann Claus
- Oberdick Georg
- Otto Marc
- Oury Hans
- Parker Andrew
- Patrick David
- Piatti Marco
- Plaksen Evgeny
- Plogmann Dieter
- Plötz Peter A.
- Plüss Andreas
- Reitgassl Frank
- Ries Gerhard
- Rinella Eugenio
- Rohr Norman
- Roman Johan
- Roth Balz
- Rubner Dennis
- Ruchti Christoph
Coaches & jurors (R-Z)

Ruegg Jörg
Rütti Willi
Salameh Constantin
Samanta Fredrik
Schaepman Ellert
Scharf Oliver
Scheller Gerd
Schenkel Philippe
Schiffer Penny
Schmidkofer Simone
Schneider Shila
Schneider Martin
Schubiger Franz
Schwarz Gabriele
Schwarz Philipp
Schwarzenbach Andy
Seidel Alex
Sethi Anil
Spierenburg Pieter
Spycher Bernard
Steinberger Philipp
Steiner Roger
Steiner Ulrich
Stephan Véronique
Stettler Christoph
Suter Christian
Szijarto Jean-Stéphane
Tesch Reto
Tripet Jean-Phillippe
Ullmann Fredrik
Val Marcos
Valentine Graham
Van de Velde Paul
van den Toorn Willemien
Vass Francesco
Vonesch Peter J.
Wagner Karen
Weidlich Hanspeter
Wensauer Dominik
Wibmer Jeannette
Widmer Simon
Wüthrich-Hasenhöhler Roger
Wyss Peter
Zbinden Richard

Contact

office
Phone: +41 (0)58 332 23 30
Fax: +41 (0)44 876 91 03
office@venture.ch
www.venture.ch

Imprint

venture 2015 is a joint initiative of ETH Zurich,
Knecht Holding AG, the federal innovation promotion agency
CTI, and McKinsey & Company Switzerland.

Team photos and project descriptions were provided
by the participating teams.

Editing: Lea Firmin and Lukas Kauz, venture office
Design: retozollinger.ch

Reproduction of the contents of this booklet is authorized,
provided the source is acknowledged.

Zurich, June 2015
We came from an academic research background and had no contact with investors or the pharmaceuticals industry. >>>venture>>> facilitated those contacts for us and we received some positive feedback. >>>venture>>> provided the catalyst to found our company.

Dominik Escher, ESBATech

For our ideas it was the ideal platform, and it helped us develop the business plan. >>>venture>>> granted us access to a network of professionals as well as exchange with other young start-ups.

Andreas, Christian, Daniel and Reto Frei, Tibits

The testimonials are picked out of our freshly released anniversary book with the title >>>venture>>> graduates go to the top. The book is available after the award ceremony in our foyer for a special price and on amazon.